Table 3.
Effects of Sustained Treatment and Delaying Treatment
| Effect | Sustained Treatment Effect After 12 Months*
|
Effect of Delaying Treatment for 12 Months†
|
||||
|---|---|---|---|---|---|---|
| Percentage Point Change From 12 to 24 Months | SE | P | Percentage Point Change From Baseline | SE | P | |
| PA spine | 2.63 | 1.00 | .009 | 1.75 | 0.84 | .038 |
| Lateral spine | 5.10 | 1.74 | .004 | 1.11 | 1.59 | .489 |
| Femoral neck | 1.48 | 1.07 | .171 | 2.21 | 0.83 | .009 |
| Trochanter | 2.07 | 0.79 | .010 | 1.14 | 0.70 | .103 |
| Total hip | 1.67 | 0.71 | .019 | 1.01 | 0.54 | .064 |
| One-third distal radius | 2.24 | 0.80 | .005 | 1.19 | 0.63 | .062 |
| Ultradistal radius | 2.09 | 0.90 | .021 | 2.76 | 0.68 | < .0001 |
| Total distal radius | 2.20 | 0.61 | < .0001 | 1.88 | 0.48 | .0001 |
Abbreviation: PA, posteroanterior.
*
Sustained treatment effect: Alendronate-alendronate versus alendronate-placebo.
†
Effect of delaying treatment by 1 year: baseline to 12 months percentage change in combined alendronate-alendronate and alendronate-placebo groups v baseline to 24 months percentage change in placebo-alendronate group. Assessed after receiving treatment for 12 months.